Cantor Fitzgerald Has Positive View of YMAB FY2024 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Research analysts at Cantor Fitzgerald boosted their FY2024 earnings estimates for Y-mAbs Therapeutics in a research report issued on Monday, November 11th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings per share of ($0.66) for the year, up from their previous estimate of ($0.67). Cantor Fitzgerald currently has a “Overweight” rating and a $20.00 target price on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share.

A number of other brokerages have also recently commented on YMAB. Canaccord Genuity Group restated a “buy” rating and set a $26.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Morgan Stanley reduced their target price on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 13th. Finally, Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.14.

Y-mAbs Therapeutics Price Performance

Shares of Y-mAbs Therapeutics stock opened at $13.18 on Thursday. The company’s fifty day moving average price is $14.08 and its two-hundred day moving average price is $13.13. Y-mAbs Therapeutics has a 52-week low of $5.04 and a 52-week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. During the same quarter in the previous year, the firm posted ($0.18) EPS.

Institutional Trading of Y-mAbs Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Y-mAbs Therapeutics in the 3rd quarter valued at about $44,000. Ameritas Investment Partners Inc. boosted its stake in Y-mAbs Therapeutics by 39.9% in the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after acquiring an additional 1,056 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after acquiring an additional 3,416 shares during the period. Intech Investment Management LLC acquired a new position in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $133,000. Finally, SG Americas Securities LLC bought a new position in shares of Y-mAbs Therapeutics in the 3rd quarter worth $178,000. 70.85% of the stock is owned by institutional investors.

Insider Activity

In related news, COO Joris Wilms sold 5,000 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the transaction, the chief operating officer now owns 30,600 shares in the company, valued at $449,514. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now owns 30,600 shares in the company, valued at $449,514. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Thomas Gad sold 65,000 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $13.47, for a total value of $875,550.00. Following the completion of the transaction, the insider now owns 97,681 shares in the company, valued at $1,315,763.07. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 100,000 shares of company stock worth $1,338,100. 22.50% of the stock is owned by corporate insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.